Associations between candidate genes with schizophrenia susceptibility and the treatment efficiency;Analiza genów kandyduja̧cych zwia̧zanych z predyspozycja̧ do schizofrenii i z efektem leczenia przeciwpsychotycznego

Psychiatria Polska

Volumn 45, Issue 6, 2011, Pages 811-823

  Tybura, Piotr ^a   Grzywacz, Anna ^a   Samochowiec, Agnieszka ^a   Samochowiec, Jerzy ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Farmacogenetics; Polymorphism; Schizophrenia

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; CATECHOL METHYLTRANSFERASE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; GENOMIC DNA; KAINIC ACID RECEPTOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; CARRIER PROTEIN; MEMBRANE PROTEIN; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; DISEASE PREDISPOSITION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MENTAL DISEASE; NEUROLOGIC DISEASE; PARANOID SCHIZOPHRENIA; PSYCHOSOMATIC DISORDER; THERAPY EFFECT; ADULT; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; DRUG EFFECT; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; POLAND; PSYCHOLOGY; QUALITY OF LIFE;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; POLAND; POLYMORPHISM, GENETIC; QUALITY OF LIFE; SCHIZOPHRENIA, PARANOID; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84155175842     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Gogos JA, Gerber D. Schizophrenia susceptybility genes: emergencje of positional candidates and future directions. Focus the Journal of Lifelong Learning in Psychiatry Summer 2006; Vol. IV; No3: 369-77.
2. Kay SR, Fiszbein A, Opler L. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin 1987, 13/2: 261-276. (Pubitemid 18039085)
3. Everitt BS, Vessely S. Clinical Trials in Psychiatry, 2nd Edition. Wiley, January 2008
4. Miller S, Dykes D, Plesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215, 1988.
5. Saiki RK, Scharf SJ, Faloona F, Mullis KB, Horn GT, Erlich HA, Arnheim N. Enzymatic amplification of beta - globin sequence and restriction site analysis for diagnosis of sickle cell anemia. Science 230: 1350-1354, 1985. (Pubitemid 16105164)
6. Grodzicker T, Williams J, Sharp P, Sambrook J. Physical mapping of temperature - sensitive mutations of adenoviruses. Cold Spring Harb Symp Quant Biol, 39 Pt 1, 439-446, 1975.
7. Li T, Yang L, Wiese C, Xu CT, Zeng Z, Giros B, Caron MG, Moises HW, Liu X. No association between alleles or genotypes at the dopamine transporter gene and schizophrenia. Psychiatry Res 1994; 52(1): 17-23. (Pubitemid 24158100)
8. Daniels J, Williams J, Asherson P, McGuffin P, Owen M. No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). Am J Med Genet 1995; 60(1): 85-7.
9. Hauser J, Kapelski P, Czerski PM, Godlewski S, Dmitrzak-Weglarz M, Twardowska K, Rybakowski JK. Lack of association between VNTR polymorphism of DAT gene and schizophrenia. Psychiatr Pol. 2002, May-Jun; 36(3): 403-12 (Pubitemid 34839021)
10. Kapelski P, Hauser J, Skibińska M, Szczepankiewicz A, Dmitrzak-Wȩglarz M, Gorzkowska K, Pawlak J, Czerski P. Asocjacyjne badania rodzinne polimorfizmów genów DRD1, DRD2, DRD3, DRD4, DAT, COMT w schizofrenii. Psychiatr Pol 2010, 3, 405-13.
11. Gamm F, Faraone SV, Glatt SJ, Yeh YC, Tsuang MT. Meta-analysis shows schizophrenia is not associated with 40-base-pair repeat polymorphism of the dopamine transporter gene. Schizophr res 2005; 1; 73(1):55-8.
12. Hori H, Ohmori O, Shinkai T, Kojima H, Nakamura J. Association analysis between two functional dopamine D2 receptor gene polymorphisms and schizophrenia. Am J Med Genet 2001; 105(2): 176-8. (Pubitemid 32290583)
13. Li T, Arranz M, Aitchison KJ, Bryant C, Liu X, Kerwin RW, Murray R, Sham P, Collier DA. Case control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia. Schizophr Res 1998; 32: 87-92. (Pubitemid 28364713)
14. Kapelski P, Czerski PM, Godlewski S, Dmitrzak-Weglarz M, Hauser J. Lack of association between 141C Ins/Del promoter polymorphism of DRD2 gene and schizophrenia. Psychiatr Pol. 2002 May-Jun; 36(3):413-9. (Pubitemid 34839022)
15. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Human Molecular Genetics 1997; 6(4): 577-582. (Pubitemid 27142107)
16. Ohara K, Nagai M, Tani K, Nakamura Y, Ino A, Ohara K. Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. Psychiatry Res 1998; 81(2): 117-23. (Pubitemid 28526968)
17. Breen G, Brown J, Maude S, Fox H, Collier D, Li T, Arranz M, Shaw D, StClair D. -141 C del/ins polymorphism of the dopamine receptor 2 gene is associated with schizophrenia in a British population. Am J Med Genet 1999; 88(4): 407-10. (Pubitemid 29372255)
18. Ambrosio AM, Kennedy JL, Macciardi F, et all. Family association study between DRD2 and DRD3 gene polymorphisms and schizophrenia in Portuguese population. Psychiatry Res. 2004; 124(3): 185-91.
19. Behravan J, Hemayatkar M, Toufani H, Abdollahian E. Linkage and Association of DRD2 Gene TaqI Polymorphism with Schizophrenia in an Iranian Population. Arch Iran Med 2008 May; 11(3): 252-6. (Pubitemid 351795794)
20. Dubertret C, Gorwood P, Gouya L, Deybach JC, Ades J. Association excess of transmission of DRD2 haplotype in sample of French schizophrenic Patients. Schizophr Res 2001; 49: 203-12. (Pubitemid 32434326)
21. Li T., Sham P.C., Vallada H., Xie T., Tang X., Murray R.M., Liu X., Collier D.A. Preferential transmission of the high activity allele of COMT in schizophrenia. Psychiatr Genet 1996; 6: 131-3. (Pubitemid 26371954)
22. Kunugi H., Vallada H.P., Sham P.C., Hoda F., Arranz M.J., Li T., Nanko S., Murray R.M., McGuffin P., Owen M., Gill M., Collier D.A. Catechol-o-methyltransferase polymorphisms and schizophrenia: transmission disequilibrium study in multiply affected families. Psychiatr Genet 1997; 7: 97-101. (Pubitemid 27450083)
23. Ohmori O., Shinkai T., Kojima H., Terao T., Suzuki T., Mita T., Abe K.: Association study of functional catechol-o-methyltransferase gene polymorphism in Japanese schizophrenics. Neuroscience Letters 1998; 109-12. (Pubitemid 28109423)
24. Jin-Bo Fan, Chang-Shun Zhang, Niu-Fan Gu, Xing-Wang Li, Wei-Wei Sun, Hong-Yan Wang, Guo-Yin Feng, David St. Clair, Lin He: Catechol-O- methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis. Biological Psych 2005; Vol 57 (2): 139-44.
25. DeLisi LE, Wise CD, Potkin SG, Zalcman S, Phelps BH, Lovenberg W, Wyat RJ. Dopamine-beta -hydroxylase, monoamino oxydase, and schizophrenia. Biol. Psych. 1980; 6: 895-907.
26. Norton N, Kirov G, Zammit S, Jones G, Jones S, Owen R, Krawczak M, Wiliams NM, O'Donowan MC, Owen MJ. Schizophrenia and functional polymorphisms in the MAOA and COMT genes: No evidence for association or epistasis. Am J Med Genet 2002; 5:491-6. (Pubitemid 34680573)
27. Stöber G, Jatzke S, Heils A, Jungkunz G, Fuchs E, Knapp M, Riederer P, Lesch KP. Susceptibility for schizophrenia is not influenced by a functional insertion/deletion variant in the promoter of the serotonin transporter gene. Eur Arch Psychiatry Clin Neurosci 1998: 248(2): 82-6. (Pubitemid 28279549)
28. de Oliveira JR, Otto PA, Vallada H, Lauriano V, Elkis H, Lafer B, Vasquez L, Gentil V, Passos-Bueno MR, Zatz M. Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brazilian patients affected by bipolar disorder and schizophrenia. Am J Med Genet 1998; 81(3): 225-7. (Pubitemid 28211183)
29. Kapelski P, Hauser J, Dmitrzak-Weglarz M, Skibińska M, Słopień A, Kaczmarkiewicz-Fass M, Rajewska A, Gattner K, Czerski PM. Lack of association between the insertion/deletion polymorphism in the serotonin transporter gene and schizophrenia. Psychiatr Pol. 2006 Sep-Oct;40(5):925-35. (Pubitemid 44763663)
30. Kapelski P, Hauser J, Skibińska M, Szczepankiewicz A, Dmitrzak-Weglarz M, Budziński B, Gorzkowska K, Czerski PM. Lack of association between the insertion/deletion polymorphism in serotonin transporter gene, T102C polymorphism of the 5HT2A receptor gene and schizophrenia family based study. Psychiatr Pol. 2010 Mar-Apr;44(2):197-206.
31. Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Korner J, Bondy B, Chen K, Shih JC, Knapp M, Propping P, Nothen MM. Systematic screening for mutations in the human serotonin 2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 1996; 97: 614-9.
32. Tay AH, Lim LC, Lee WL, Wong KE, Wong LY, Tsoi WF. Association between allele 1 of T102C polymorphism, 5-hydroxytryptamine 2a receptor gene and schizophrenia in Chinese males in Singapore. Hum Hered 1997; 47(5): 298-300. (Pubitemid 27434547)
33. Abdolmaleky HM, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of assotiation between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 2004 Mar 1; 67(1): 53-62. (Pubitemid 38117091)
34. Badner JA, Garshon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 2002; 7(4): 404-11.
35. Li D, Duan Y, He L. Association study of serotonin 2A receptor (5HT2A) gene with schizophrenia and suicidal behavior using systematic meta-analysis. Biochem Biophys Res Commun 2006 Feb 17; 340(3): 1006-15. (Pubitemid 43053926)
36. Lai IC, Liou YJ, Chen JY, Wang YC. No association between the ionotropic glutamate receptor kainite 3 (GRIK 3) ser310ala polymorphism and schizophrenia. Neuropsychobiology 2005; 51(4): 211-3.
37. Begni S, Popoli M, Moraschi S, Bignotti S, Tura GB, Gennarelli M. Association between the ionotropic glutamate receptor kainite 3 (GRIK 3) ser310ala polymorphism and schizophrenia. Mol. Psychiatry 2002; 7: 416-418. (Pubitemid 34499364)
38. Lencz T, Robinson DG, Xu K, Ekholm J, Sevy S, Gunduz-Bruce H et al. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006; 163: 529-31. (Pubitemid 44469398)
39. Schafer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 2001; 158: 802-4. (Pubitemid 32429852)
40. Wu S, Xing Q, Gao R, Li X, Gu N, Feng G et al. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neurosci Lett 2005; 376: 1-4.
41. Weickert TW, Goldberg TE, Mishara A, Apud JA, Kolachana BS, Egan MF et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol Psychiatry 2004; 56: 677-82. (Pubitemid 39446850)
42. Woodward ND, Jayathilake K, Meltzer HY. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr Res 2007; 90: 86-96. (Pubitemid 46177559)
43. Herken H., Erdal M.E. Catechol-o-methyltransferase gene polymorphism in symptomatology and prognosis. Psychiatric Genetics 2001; 11:105-9.
44. Kirchheiner J., Nickchen K., Bauer M., Wong M-L., Licinio J., Roots I., Brockmoller J. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry 2004; 9: 442-73. (Pubitemid 38903502)
45. Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998; 32: 93-9. (Pubitemid 28364714)
46. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 2002; 159: 1593-5.
47. Arranz MJ, Munro J, Birkett J, Bolonna AA, Mancama D, Sodhi M et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355: 1615-6. (Pubitemid 30240510)
48. Tybura P, Grzywacz A, Syrek S, Parus M, Samochowiec J. Association of functional genes polymorphisms of key enzymes in the metabolism of biogenic amines with paranoid schizophrenia susceptibility and the influence of these polymorphisms on PANSS results in antipsychotic treatment. Psychiatr Pol. 2006, 5: 913.